Format

Send to

Choose Destination
JAMA Oncol. 2016 Nov 1;2(11):1397-1398. doi: 10.1001/jamaoncol.2016.2463.

Direct-to-Consumer Drug Advertising in Oncology Is Not Beneficial to Patients or Public Health.

Author information

1
Division of Hematology-Oncology and Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.
2
Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
PMID:
27532895
DOI:
10.1001/jamaoncol.2016.2463
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center